REFERENCES

1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934-59.

2. Pinchot SN, Holen K, Sippel RS, Shen H. Carcinoid tumors. Oncologist 2008;13:1255-69.

3. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist 2005;10:123-31.

4. Karcioglu ZA. Orbital tumours: Diagnosis and treatment. 2nd ed. New York: Springer; 2005. pp. 187-9.

5. Peixoto RD, Lim HJ, Cheung WY. Neuroendocrine tumor metastatic to the orbit treated with radiotherapy. World J Gastrointest Oncol 2013;5:177-80.

6. Mehta JS, Abou-Rayyah Y, Rose GE. Orbital carcinoid metastases. Ophthalmology 2006;113:466-72.

7. Borota OC, Kloster R, Lindal S. Carcinoid tumour metastatic to the orbit with infiltration to the extraocular orbital muscle. APMIS 2005;113:135-9.

8. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169-88.

9. Rinke A, Müller HH, Schade-brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors. J Clin Oncol 2009;27:4656-63.

10. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Seedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Lanley A, Martinez S, Blumberg J, Ruszniewski P. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. N Engl J Med 2014;371:224-33.